A reply to “Comment on: ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer”

We would like to thank Yuji Inagaki and Akihiro Tamiya for their comment on our recent publication ‘Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer’.

Source: Lung Cancer - August 7, 2020 Category: Cancer & Oncology Authors: Bianca van Veggel, Adrianus Johannes de Langen Source Type: research